 | • レポートコード：MRC2303I0110 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界のDNA修復薬市場規模が、予測期間中（2022年〜2027年）に年平均13%で成長すると予測しています。本レポートは、DNA修復薬の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬種類別（オラパリブ、ルカパリブ、ニラパリブ、タラゾパリブ、その他）分析、用途別（卵巣がん、卵管がん、腹膜がん、乳がん、その他）分析、流通チャンネル別（病院薬局、小売薬局、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Onxeo、FoRx Therapeutics、Artios Pharma Limited、Merck KGaA、Debiopharm Group、Breakpoint Therapeutics、Luciole Pharmaceuticals、Repare Therapeutics、AstraZeneca Plc、AbbVie、Johnson & Johnson、Pfizer Inc.、ClovisOncology Inc.、GlaxoSmithKline plc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のDNA修復薬市場規模：薬種類別 - オラパリブの市場規模 - ルカパリブの市場規模 - ニラパリブの市場規模 - タラゾパリブの市場規模 - その他薬種類の市場規模 ・世界のDNA修復薬市場規模：用途別 - 卵巣がんにおける市場規模 - 卵管がんにおける市場規模 - 腹膜がんにおける市場規模 - 乳がんにおける市場規模 - その他用途における市場規模 ・世界のDNA修復薬市場規模：流通チャンネル別 - 病院薬局チャンネルの市場規模 - 小売薬局チャンネルの市場規模 - その他チャンネルの市場規模 ・世界のDNA修復薬市場規模：地域別 - 北米のDNA修復薬市場規模 アメリカのDNA修復薬市場規模 カナダのDNA修復薬市場規模 メキシコのDNA修復薬市場規模 … - ヨーロッパのDNA修復薬市場規模 ドイツのDNA修復薬市場規模 イギリスのDNA修復薬市場規模 フランスのDNA修復薬市場規模 … - アジア太平洋のDNA修復薬市場規模 中国のDNA修復薬市場規模 日本のDNA修復薬市場規模 インドのDNA修復薬市場規模 … - 中東/南米のDNA修復薬市場規模 南アフリカのDNA修復薬市場規模 ブラジルのDNA修復薬市場規模 アルゼンチンのDNA修復薬市場規模 … - その他地域のDNA修復薬市場規模 ・競争状況 ・市場機会・将来の動向 |
The DNA repair drugs market is expected to register a CAGR of nearly 13% over the forecast period, 2022-2027.
The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the DNA repair drugs market. DNA repair drugs are majorly used for cancer. Thus, the delay in cancer treatment worldwide significantly impacted the demand for these drugs after the onset of the pandemic. For instance, according to a research study published in May 2021, titled “Impact of COVID-19 on Cancer Care in India: A Cohort Study”, the COVID-19 epidemic has significantly impacted how oncology services are provided in India and the progression of cancer stages and outcomes, discontinuing cancer screening and delaying hospital visits are likely to have significant long-term effects. Therefore, COVID-19 had a significant impact on the DNA repair drugs market, however, with the decline in COVID-19 cases and universal vaccination programs, the studied market is expected to regain its full potential over the forecast period.
Also, as per a February 2021 published article titled, “Dramatic drop in new cancer drug trials during the COVID-19 pandemic”, the data revealed a 60% decrease in new clinical trials for cancer drugs and biological therapies during the pandemic, further highlighting the Impact that COVID-19 is having on oncology research. This further indicates the slow growth of the market amid the pandemic. Moreover, COVID-19 also led to supply chain disruptions of pharmaceutical and biotechnology products. However, the scope of market growth is expected to expand amid the pandemic with the introduction of vaccines, upliftment of lockdown restrictions, and resuming research and development activities across the globe in the coming period.
The growth of the market studied can be largely attributed to the factors such as the growing burden of cancer worldwide and the increasing research and development of novel drugs and treatments. These factors are leading to increasing demand for DNA repair drugs.
The growing burden of cancer is driving the demand for DNA repair drugs. PARP inhibitors are a type of DNA repair cancer drug and are used for the treatment of various types of cancers and are also in trials as a treatment for other types of cancers. As per GLOBOCAN 2020, the estimated number of new cases in 2020 was about 19.3 million, and the number is expected to reach nearly 30.2 million by the year 2040. This is likely to provide ample opportunities for the market studied.
Additionally, the increasing research and development for novel drugs and treatments are driving the market growth. For instance, in August 2021, the United Kingdom firm Artios Pharma raised a Series C round of EUR 129 million to develop cancer drugs that target the DNA repair systems of cells. Also, in April 2020, FoRx Therapeutics raised EUR 10 million in seed funding to develop a new generation of drugs that target DNA repair in cancer cells. Thus, the anticipated increase in the burden of cancer is driving the demand for DNA repair drugs. However, the delays witnessed in product approval which can affect the revenue generation as well as lead to an increase in the cost of clinical trials is a factor that is majorly restraining the market growth.
DNorth America Repair Drugs Market Trends
Olaparib Segment is Expected to Hold a Major Market Share in the DNA Repair Drugs Market Over Forecast Period
By drug type, olaparib is expected to hold a major share in the market. Olaparib is sold under the brand name Lynparza. It is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.
The major factors bolstering the growth of the segment are the growing burden of ovarian cancer, breast cancer, pancreatic cancer, peritoneal cancer, fallopian tube cancer, and prostate cancer. For instance, according to the World Cancer Research Fund International, ovarian cancer is the 8th most commonly occurring cancer in women and the 18th most common cancer overall, and there were more than 313,000 new cases of ovarian cancer in 2020. Additionally, according to GLOBOCAN 2020, the estimated number of new cases of breast cancer cases in 2020 was 2.26 million, and the number is estimated to reach 3.19 million by the year 2040.
Several market players are also engaged in the implementation of strategic initiatives that are contributing to market growth. For instance, in March 2022, AstraZeneca and MSD’s Lynparza (olaparib) was approved in the United States for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. This factor is anticipated to boost the growth of the segment.
North America is Anticipated to Observe a Significant Growth in the DNA Repair Drugs Market Over Forecast Period
The factors fueling the market growth in the region are the increasing focus on research and development, the growing number of investments pertaining to DNA repair research as well as the increasing burden of cancer disorders in the country. For instance, as per the 2020 Statistics by the National Cancer Institute (NCI), about 1,806,590 cases of cancer were diagnosed in the United States in 2020, and the number of cancer survivors is projected to reach 2.2 million by 2030. Moreover, as per the NCI, in 2021, the most prevalent cancer type is breast cancer, with 284,200 cases. These factors are leading to an increased demand for DNA repair drugs in the region.
Additionally, according to March 2022 update by the Florida State University, a Florida State University College of Medicine researcher has made a discovery that alters the understanding of how the body’s DNA repair process works and may lead to new chemotherapy treatments for cancer and other disorders. This indicates that the increasing focus on research and development can boost the development of DNA repair drugs that can augment the market growth in the region. Also, in March 2022, the United States Food and Drug Administration approved AstraZeneca and MSD’s Lynparza (olaparib) for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. Thus, due to the above-mentioned developments, the regional market is expected to witness significant growth over the forecast period.
DNorth America Repair Drugs Market Competitor Analysis
The DNA repair drugs market is nearly consolidated with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are AstraZeneca plc, Clovis Oncology, GlaxoSmithKline plc., Pfizer Inc., and Onxeo.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cancer Worldwide
4.2.2 Increasing Research and Development for Novel Drugs and Treatment
4.3 Market Restraints
4.3.1 Strict Regulation for Product Approval
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Drug Type
5.1.1 Olaparib
5.1.2 Rucaparib
5.1.3 Niraparib
5.1.4 Talazoparib
5.1.5 Other Drug Types
5.2 By Application
5.2.1 Ovarian Cancer
5.2.2 Fallopian Tube Cancer
5.2.3 Peritoneal Cancer
5.2.4 Breast Cancer
5.2.5 Other Application Types
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Other Distribution Channel
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Rest of World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Onxeo
6.1.2 FoRx Therapeutics
6.1.3 Artios Pharma Limited
6.1.4 Merck KGaA
6.1.5 Debiopharm Group
6.1.6 Breakpoint Therapeutics
6.1.7 Luciole Pharmaceuticals
6.1.8 Repare Therapeutics
6.1.9 AstraZeneca Plc
6.1.10 AbbVie
6.1.11 Johnson & Johnson
6.1.12 Pfizer Inc.
6.1.13 ClovisOncology Inc.
6.1.14 GlaxoSmithKline plc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS